US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Maze Therapeutics

9.13

+0.72008.56%

Volume:100.50K

Turnover:882.10K

Market Cap:399.86M

PE:7.30

High:9.16

Open:8.38

Low:8.33

Close:8.41

Loading ...

Overview Company News Filings

Maze Therapeutics Price Target Maintained With a $19.00/Share by Guggenheim

TD Cowen Keeps Their Buy Rating on Maze Therapeutics, Inc. (MAZE)

Maze Therapeutics Q4 2024 GAAP EPS $(18.32) Vs. $(11.46) YoY, Raised $140M In Gross Proceeds In Upsized IPO In February 2025, Providing Expected Cash Runway Into H2 2027

Maze Therapeutics reports Q4 EPS ($18.32) vs ($11.46) last year

Maze Therapeutics Inc -Qtrly Shr Loss $18.32

THOMSON REUTERS

Maze Therapeutics Inc -Expects Current Cash & Cash Equivalents to Fund Operations Into Second Half of 2027

THOMSON REUTERS

Press Release: Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights

Maze Therapeutics receives positive ratings following recent IPO

BUZZ-Maze Therapeutics rises as brokerages initiate coverage post research quiet period

Maze Therapeutics Inc : TD Cowen Initiates Coverage With Buy Rating

THOMSON REUTERS

Maze Therapeutics Inc : Leerink Partners Initiates Coverage With Outperform Rating; Target Price $28

THOMSON REUTERS

TD Cowen Initiates Maze Therapeutics at Buy

MT Newswires Live

Guggenheim Initiates Maze Therapeutics at Buy With $19 Price Target

MT Newswires Live

Leerink Partners Initiates Maze Therapeutics at Outperform With $28 Price Target

MT Newswires Live

JPMorgan Initiates Maze Therapeutics at Overweight With $30 Price Target

MT Newswires Live

Maze Therapeutics Inc : JP Morgan Initiates Coverage With Overweight Rating; Price Target $30

THOMSON REUTERS

Maze Therapeutics Initiated at Overweight by JP Morgan

Maze Therapeutics initiated with a Buy at TD Cowen

Promising Drug Candidates and Market Potential Drive Buy Rating for Maze Therapeutics

Maze Therapeutics, Inc.: Buy Rating Backed by Promising Pipeline and Lead Asset MZE829

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/MAZE/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MAZE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MAZE\",,,,,undefined,":{"symbol":"MAZE","market":"US","secType":"STK","nameCN":"Maze Therapeutics","latestPrice":9.13,"timestamp":1745265600000,"preClose":8.41,"halted":0,"volume":100502,"delay":0,"floatShares":18431500,"shares":43796057,"eps":1.25,"marketStatus":"Pre-Mkt","change":0.72,"latestTime":"04-22 04:21:58 EDT","open":8.38,"high":9.16,"low":8.325,"amount":882100.5826,"amplitude":0.099287,"askPrice":14.51,"askSize":100,"bidPrice":8.42,"bidSize":174,"shortable":3,"etf":0,"ttmEps":1.25,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1745328600000},"marketStatusCode":1,"adr":0,"listingDate":1738299600000,"exchange":"NASDAQ","adjPreClose":9.13,"postHourTrading":{"tag":"盘后","latestPrice":9.13,"preClose":9.13,"latestTime":"16:05 EDT","volume":246,"amount":2245.98,"timestamp":1745265907837},"volumeRatio":0.6577356017498767},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MAZE\",,,,,undefined,":{"symbol":"MAZE","floatShares":18431500,"roa":"23.07%","roe":"50.47%","lyrEps":1.421062,"volumeRatio":0.6577356017498767,"shares":43796057,"dividePrice":0,"high":9.16,"amplitude":0.099287,"preClose":8.41,"low":8.325,"week52Low":6.71,"pbRate":"-1.28","psRate":"2.39","week52High":17,"institutionHeld":0,"latestPrice":9.13,"committee":0.270073,"eps":1.25,"divideRate":0,"volume":100502,"delay":0,"ttmEps":1.25,"open":8.38,"prevYearClose":16,"prevWeekClose":8.41,"prevMonthClose":11.01,"prevQuarterClose":11.01,"fiveDayClose":7.83,"twentyDayClose":11.14,"sixtyDayClose":16},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MAZE\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2524415108","title":"Maze Therapeutics Price Target Maintained With a $19.00/Share by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2524415108","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524415108?lang=en_us&edition=fundamental","pubTime":"2025-04-02 23:54","pubTimestamp":1743609240,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MAZE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 02, 2025 11:54 ET (15:54 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE"],"gpt_icon":0},{"id":"2524148426","title":"TD Cowen Keeps Their Buy Rating on Maze Therapeutics, Inc. (MAZE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2524148426","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524148426?lang=en_us&edition=fundamental","pubTime":"2025-04-01 22:25","pubTimestamp":1743517520,"startTime":"0","endTime":"0","summary":"In a report released today, Tyler Van Buren from TD Cowen maintained a Buy rating on Maze Therapeutics, Inc. (MAZE – Research Report). The company’...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/td-cowen-keeps-their-buy-rating-on-maze-therapeutics-inc-maze?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/td-cowen-keeps-their-buy-rating-on-maze-therapeutics-inc-maze?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TD","MAZE","COWN"],"gpt_icon":0},{"id":"2523948901","title":"Maze Therapeutics Q4 2024 GAAP EPS $(18.32) Vs. $(11.46) YoY, Raised $140M In Gross Proceeds In Upsized IPO In February 2025, Providing Expected Cash Runway Into H2 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2523948901","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523948901?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:39","pubTimestamp":1743421182,"startTime":"0","endTime":"0","summary":"Maze Therapeutics Q4 2024 GAAP EPS $(18.32) Vs. $(11.46) YoY, Raised $140M In Gross Proceeds In Upsized IPO In February 2025, Providing Expected Cash Runway Into H2 2027","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/general/biotech/25/03/44559054/maze-therapeutics-q4-2024-gaap-eps-18-32-vs-11-46-yoy-raised-140m-in-gross-proceeds-in-upsized-ip","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE"],"gpt_icon":0},{"id":"2523594338","title":"Maze Therapeutics reports Q4 EPS ($18.32) vs ($11.46) last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2523594338","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523594338?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:36","pubTimestamp":1743420986,"startTime":"0","endTime":"0","summary":"“Maze has reached a pivotal moment in our journey. On the heels of a successful IPO and with two ongoing clinical-stage programs – MZE829 for AKD a...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maze-therapeutics-reports-q4-eps-18-32-vs-11-46-last-year?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maze-therapeutics-reports-q4-eps-18-32-vs-11-46-last-year?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAZE"],"gpt_icon":0},{"id":"2523948573","title":"Maze Therapeutics Inc -Qtrly Shr Loss $18.32","url":"https://stock-news.laohu8.com/highlight/detail?id=2523948573","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523948573?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:32","pubTimestamp":1743420769,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nFWN3QC0B0:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MAZE","BK4007"],"gpt_icon":0},{"id":"2523485509","title":"Maze Therapeutics Inc -Expects Current Cash & Cash Equivalents to Fund Operations Into Second Half of 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2523485509","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523485509?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:32","pubTimestamp":1743420769,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nFWN3QC0B0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MAZE"],"gpt_icon":0},{"id":"2523948396","title":"Press Release: Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2523948396","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523948396?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:30","pubTimestamp":1743420600,"startTime":"0","endTime":"0","summary":"MZE829 Phase 2 HORIZON Trial Enrolling Patients with APOL1 Kidney Disease ; Initial Data Expected in Q1 2026. MZE782 Phase 1 Healthy Volunteer Trial Ongoing; Initial Data Expected in H2 2025. Raised $140 Million in Gross Proceeds in Upsized IPO in February 2025, Providing Expected Cash Runway into H2 2027. SOUTH SAN FRANCISCO, Calif., March 31, 2025  -- Maze Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with renal, cardiovascular and metabolic diseases, today reported financial results for the fourth quarter and year ended December 31, 2024, highlighted recent progress and reiterated upcoming milestones.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FSGS","MAZE","BK4007"],"gpt_icon":0},{"id":"2514704435","title":"Maze Therapeutics receives positive ratings following recent IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2514704435","media":"Investing.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514704435?lang=en_us&edition=fundamental","pubTime":"2025-02-26 05:11","pubTimestamp":1740517867,"startTime":"0","endTime":"0","summary":"Investing.com -- Maze Therapeutics Inc received bullish coverage from multiple analysts, with Guggenheim, JPMorgan, and TD Cowen initiating Buy or Overweight ratings on the company given its potential in genetically targeted therapies.Maze's lead drug candidate, MZE829, is an oral APOL1 inhibitor being developed for APOL1-mediated kidney disease. Analysts expect key Phase II HORIZON trial data in early 2026, with TD Cowen highlighting its potential to address over 1 million AKD patients and noting its potency advantage over Vertex's  inaxaplin. Guggenheim sees Maze as a compelling investment, given the estimated $10 billion to $15 billion market opportunity in APOL1-associated kidney disease.Beyond MZE829, Maze's pipeline includes MZE782, an SLC6A19 inhibitor targeting chronic kidney disease and phenylketonuria, with Phase I data expected in the second half of 2025. Analysts view it as a first-in-class therapy with significant commercial potential.JPMorgan, which set a $30 price target","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/maze-therapeutics-receives-positive-ratings-211107907.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MAZE"],"gpt_icon":0},{"id":"2514968019","title":"BUZZ-Maze Therapeutics rises as brokerages initiate coverage post research quiet period","url":"https://stock-news.laohu8.com/highlight/detail?id=2514968019","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514968019?lang=en_us&edition=fundamental","pubTime":"2025-02-26 00:13","pubTimestamp":1740499987,"startTime":"0","endTime":"0","summary":"BUZZ-Maze Therapeutics rises as brokerages initiate coverage post research quiet period** Shares of Maze Therapeutics MAZE.O rise 4.8% to $11.34 ** Wall Street brokerages start coverage of the drug de","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nL3N3PG1OA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4589","BK4007","BK4211","BK4207","SIVBQ","MAZE","BK4588"],"gpt_icon":0},{"id":"2514609960","title":"Maze Therapeutics Inc : TD Cowen Initiates Coverage With Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2514609960","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514609960?lang=en_us&edition=fundamental","pubTime":"2025-02-25 21:11","pubTimestamp":1740489109,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nFWN3PG0OR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MAZE"],"gpt_icon":0},{"id":"2514098450","title":"Maze Therapeutics Inc : Leerink Partners Initiates Coverage With Outperform Rating; Target Price $28","url":"https://stock-news.laohu8.com/highlight/detail?id=2514098450","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514098450?lang=en_us&edition=fundamental","pubTime":"2025-02-25 20:03","pubTimestamp":1740485036,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nFWN3PG0P8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MAZE","BK4007"],"gpt_icon":0},{"id":"2514067325","title":"TD Cowen Initiates Maze Therapeutics at Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2514067325","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514067325?lang=en_us&edition=fundamental","pubTime":"2025-02-25 19:22","pubTimestamp":1740482522,"startTime":"0","endTime":"0","summary":"TD Cowen Initiates Maze Therapeutics at Buy","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","BK4007","MAZE","TD","COWN","BK4207","BK4127","BK4566"],"gpt_icon":0},{"id":"2514067327","title":"Guggenheim Initiates Maze Therapeutics at Buy With $19 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2514067327","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514067327?lang=en_us&edition=fundamental","pubTime":"2025-02-25 19:21","pubTimestamp":1740482514,"startTime":"0","endTime":"0","summary":"Guggenheim Initiates Maze Therapeutics at Buy With $19 Price Target","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MAZE"],"gpt_icon":0},{"id":"2514067340","title":"Leerink Partners Initiates Maze Therapeutics at Outperform With $28 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2514067340","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514067340?lang=en_us&edition=fundamental","pubTime":"2025-02-25 19:21","pubTimestamp":1740482507,"startTime":"0","endTime":"0","summary":"Leerink Partners Initiates Maze Therapeutics at Outperform With $28 Price Target","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MAZE"],"gpt_icon":0},{"id":"2514067373","title":"JPMorgan Initiates Maze Therapeutics at Overweight With $30 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2514067373","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514067373?lang=en_us&edition=fundamental","pubTime":"2025-02-25 19:21","pubTimestamp":1740482493,"startTime":"0","endTime":"0","summary":"JPMorgan Initiates Maze Therapeutics at Overweight With $30 Price Target","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MAZE"],"gpt_icon":0},{"id":"2514064120","title":"Maze Therapeutics Inc : JP Morgan Initiates Coverage With Overweight Rating; Price Target $30","url":"https://stock-news.laohu8.com/highlight/detail?id=2514064120","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514064120?lang=en_us&edition=fundamental","pubTime":"2025-02-25 18:58","pubTimestamp":1740481104,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nFWN3PG03V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MAZE"],"gpt_icon":0},{"id":"2514199064","title":"Maze Therapeutics Initiated at Overweight by JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2514199064","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514199064?lang=en_us&edition=fundamental","pubTime":"2025-02-25 18:49","pubTimestamp":1740480540,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MAZE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 25, 2025 05:49 ET (10:49 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE"],"gpt_icon":0},{"id":"2514064852","title":"Maze Therapeutics initiated with a Buy at TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2514064852","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514064852?lang=en_us&edition=fundamental","pubTime":"2025-02-25 18:41","pubTimestamp":1740480066,"startTime":"0","endTime":"0","summary":"TD Cowen initiated coverage of Maze Therapeutics (MAZE) with a Buy rating and no price target The company’s MZE829, and oral APOL1 inhibitor, could...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maze-therapeutics-initiated-with-a-buy-at-td-cowen?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maze-therapeutics-initiated-with-a-buy-at-td-cowen?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["COWN","MAZE","BK4566","TD","BK4207","BK4585","BK4127","BK4007"],"gpt_icon":0},{"id":"2514064866","title":"Promising Drug Candidates and Market Potential Drive Buy Rating for Maze Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2514064866","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514064866?lang=en_us&edition=fundamental","pubTime":"2025-02-25 18:35","pubTimestamp":1740479737,"startTime":"0","endTime":"0","summary":"Maze Therapeutics, Inc. (MAZE) has received a new Buy rating, initiated by TD Cowen analyst, Tyler Van Buren. Tyler Van Buren has given his Buy rat...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-drug-candidates-and-market-potential-drive-buy-rating-for-maze-therapeutics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-drug-candidates-and-market-potential-drive-buy-rating-for-maze-therapeutics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAZE"],"gpt_icon":0},{"id":"2514690200","title":"Maze Therapeutics, Inc.: Buy Rating Backed by Promising Pipeline and Lead Asset MZE829","url":"https://stock-news.laohu8.com/highlight/detail?id=2514690200","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514690200?lang=en_us&edition=fundamental","pubTime":"2025-02-25 18:15","pubTimestamp":1740478550,"startTime":"0","endTime":"0","summary":"Maze Therapeutics, Inc. (MAZE) has received a new Buy rating, initiated by J.P. Morgan analyst, Anupam Rama. Anupam Rama has given his Buy rating d...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/maze-therapeutics-inc-buy-rating-backed-by-promising-pipeline-and-lead-asset-mze829?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/maze-therapeutics-inc-buy-rating-backed-by-promising-pipeline-and-lead-asset-mze829?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAZE"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":36,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MAZE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-31","symbol":"MAZE","fiscalQuarterEnding":"2024/12","expectedEps":-7.6,"name":null,"time":"","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"","actualEps":-18.32}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MAZE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MAZE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":4,"updateTime":1740715200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MAZE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MAZE","date":"2025-04-17","current":6.858987,"percent":0.092593,"low":6.347498,"twenty":8.362362,"median":9.29705,"eighty":9.98026,"high":12.681398,"avg":9.163226,"sd":1.404668,"marketCap":358251746},"quantilePoints":[{"date":"2025-01-31","current":12.681398,"twenty":12.46124,"median":12.543799,"eighty":12.626358,"marketCap":700431648},{"date":"2025-02-07","current":10.303636,"twenty":10.343265,"median":11.88881,"eighty":12.594654,"marketCap":569100714},{"date":"2025-02-14","current":8.972089,"twenty":9.94063,"median":10.40271,"eighty":12.302722,"marketCap":495555390},{"date":"2025-02-21","current":9.645788,"twenty":9.645788,"median":10.220414,"eighty":11.88881,"marketCap":532765822},{"date":"2025-02-28","current":10.081711,"twenty":9.495197,"median":10.081711,"eighty":10.604819,"marketCap":556843160},{"date":"2025-03-07","current":9.29705,"twenty":9.29705,"median":9.788453,"eighty":10.501783,"marketCap":513503951},{"date":"2025-03-14","current":8.956237,"twenty":8.972089,"median":9.582381,"eighty":10.303636,"marketCap":494679851},{"date":"2025-03-21","current":9.479345,"twenty":8.972089,"median":9.534826,"eighty":10.271932,"marketCap":523572656},{"date":"2025-03-28","current":8.93246,"twenty":8.956237,"median":9.495197,"eighty":10.168896,"marketCap":493366542},{"date":"2025-04-04","current":7.814885,"twenty":8.89283,"median":9.443679,"eighty":10.137192,"marketCap":408179251},{"date":"2025-04-11","current":6.372653,"twenty":8.695317,"median":9.384234,"eighty":10.081711,"marketCap":332850033},{"date":"2025-04-17","current":6.858987,"twenty":8.362362,"median":9.29705,"eighty":9.98026,"marketCap":358251746}],"updateTime":1745274204445}}}